LoginSignup
Alnylam Pharms logo

Alnylam Pharms Stock

StockStock
ISIN: US02043Q1076
Ticker: ALNY
US02043Q1076
ALNY

Price

Frequently asked questions

What is Alnylam Pharms's market capitalization?

The market capitalization of Alnylam Pharms is $33.27B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Alnylam Pharms?

Alnylam Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.621. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Alnylam Pharms's stock?

Currently, 28 analysts cover Alnylam Pharms's stock, with a consensus target price of $222.04. Analyst ratings provide insights into the stock's expected performance.

What is Alnylam Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Alnylam Pharms reported a revenue of $2.09B.

What is the EBITDA for Alnylam Pharms?

Alnylam Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$132.15M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Alnylam Pharms?

Alnylam Pharms has a free cash flow of $16.06M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Alnylam Pharms's stock?

The 5-year beta for Alnylam Pharms is 0.33. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Alnylam Pharms have, and what sector and industry does it belong to?

Alnylam Pharms employs approximately 2,100 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Alnylam Pharms's shares?

The free float of Alnylam Pharms is 128.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $33.27B

5Y beta

 0.33

EPS (TTM)

 -$2.621

Free Float

 128.44M

Revenue (TTM)

 $2.09B

EBITDA (TTM)

 -$132.15M

Free Cashflow (TTM)

 $16.06M

Pricing

1D span
$255.91$257.20
52W span
$141.98$304.39

Analyst Ratings

The price target is $222.04 and the stock is covered by 28 analysts.

Buy

19

Hold

9

Sell

0

Information

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

2,100

Biotechnology & Drugs

Health Care

Identifier

ISIN

US02043Q1076

Primary Ticker

ALNY

Knockouts

Join the conversation
Sign upLogin